PYREXAR Medical is the pioneer and worldwide market leader in the development and manufacturing of innovative and highly effective hyperthermia treatment systems with established global distribution. PYREXAR Hyperthermia treatments increase the effective dose of ionizing radiation in cancerous tumors up to 3X without increasing toxicity in healthy tissues.
PYREXAR HT systems deliver therapeutic heating to cancerous tumors via non-invasive radio-frequency (RF) energy. Cancer cells are hypoxic and have a low pH, making them more susceptible to the increased temperature. During the HT treatment, the solid tumor micro-environment is warmed to ~ 42˚C (108˚F) to assist in the destruction of malignant cells while preserving healthy tissues.
Multi-center clinical trials in the US, Europe, and Asia over the past 30 years document dramatic improvement in survival rates when HT is combined with radiotherapy in the treatment of chest wall recurrences after breast cancer, locally advanced cervical cancer, rectal cancer, high-risk soft tissue sarcoma, malignant melanoma, anal carcinoma, and bladder cancer.
PYREXAR HT can now be integrated within 1.5 Tesla MR systems to provide simultaneous RF heating and MR Imaging, enabling treatment of deep primary tumors of pelvis, abdomen, and lung with real-time thermometry both highly accurate and non-invasive. This new multimodality treatment approach has caused renewed interest in PHT technology as a valuable adjunct to radiotherapy, chemotherapy, and surgery.